BMRN - BioMarin Pharmaceutical Inc.
| Previous Close | 86.97 |
| Open | 87.55 |
| Bid | 88.81 x 1200 |
| Ask | 88.88 x 900 |
| Day's Range | 87.46 - 89.32 |
| 52 Week Range | 79.13 - 106.74 |
| Volume | 677,376 |
| Avg. Volume | 1,147,019 |
| Market Cap | 15.9B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Jul 31, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 119.13 |
- Barrons.com•2 days ago
BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says
J.P. Morgan analyst Cory Kasimov said Wednesday that BioMarin is undervalued. He said the firm is in strong shape, even if its gene-therapy results are disappointing.
- Zacks•8 days ago
BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- PR Newswire•8 days ago
BioMarin to Participate in 2019 RBC Capital Markets Global Healthcare Conference on May 21 in New York City
SAN RAFAEL, Calif. , May 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Robert Baffi , Ph.D., Executive Vice President, Technical Operations, will participate ...
- TheStreet.com•10 days ago
2 Stocks You Definitely Should Consider Shorting This Week
Using recent actions and grades from TheStreet's Quant Ratings and layering on technical analysis of the charts of those stocks, Trifecta Stocks identifies five names each Friday that look bearish. While we will not be weighing in with fundamental analysis we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.
- Simply Wall St.•14 days ago
Read This Before Buying BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Bloomberg•15 days agoBioMarin Bulls Are Counting on Gene Therapy to Reignite the Stock
BioMarin Pharmaceutical Inc. is set to announce results of its medicine, Valrox, that will show how durable the next-generation drug is three years after dosing. The update has been seen across Wall Street as the next key value driver for shares and could spur the stock to either rise or fall as much as 25 percent, according to Wedbush. Investors have become increasingly wary of how much the medicine’s benefit will decline compared to two-year results.
- Zacks•15 days ago
Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.
- TheStreet.com•16 days ago
Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs
The markets have been rocked this week by escalating trade tensions between the U.S. and China as well as potentially new tariffs on the horizon. As such, valrox, if efficacy is durable, has the potential to be the largest product for BioMarin.
- PR Newswire•16 days ago
BioMarin to Participate in Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas
SAN RAFAEL, Calif. , May 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank ...
- Markit•17 days ago
See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $4.13 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- American City Business Journals•17 days ago
Netflix and Google now pay a typical employee more than $200K per year. Here's how that compares to Facebook, Intel, Twitter and other big Bay Area tech employers.
Netflix and Google employees are now in Silicon Valley's $200K club. The typical Googler earned $246,804 last year — up 25 percent year-over-year. At Netflix, the median employee made $202,335 last year after getting a 10 percent pay boost over 2017.
- PR Newswire•18 days ago
European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older
First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg Treatment Lowers Phe and Suggestive of Beneficial Effects ...
- Benzinga•22 days ago
5 Biotech Stocks With Near-Term Catalysts Ahead
The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.
- Motley Fool•23 days ago
BioMarin Isn't a "Gene Therapy Company"
Despite the biotech's move into gene therapy, its bread and butter are still paying the bills.
- Thomson Reuters StreetEvents•25 days ago
Edited Transcript of BMRN earnings conference call or presentation 25-Apr-19 8:30pm GMT
Q1 2019 Biomarin Pharmaceutical Inc Earnings Call
- Zacks•28 days ago
BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat
BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.
- Benzinga•28 days ago
The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
Motley Fool•28 days agoBiomarin Pharmaceutical Inc (BMRN) Q1 2019 Earnings Call Transcript
BMRN earnings call for the period ending March 31, 2019.
- Associated Press•29 days ago
BioMarin: 1Q Earnings Snapshot
The San Rafael, California-based company said it had a loss of 32 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, came to 14 cents per share. The results beat Wall ...
- PR Newswire•29 days ago
BioMarin Announces First Quarter 2019 Financial Results
- Total Revenues Top $400 million in the Quarter - Full-year 2019 Total BioMarin Revenue Guidance of Between $1.68 billion to $1.75 billion Reaffirmed - As of March 31, 2019, 414 U.S. Commercial Patients ...
- ACCESSWIRE•29 days ago
BioMarin Pharmaceutical Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at ...
- Benzinga•29 days ago
The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...
- Zacks•last month
Solid Earnings Boost S&P, NASDAQ to New Closing Highs
Solid Earnings Boost S&P;, NASDAQ to New Closing Highs
- MoneyShow•last month
Long-Term "GameChangers" in Biotech
When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.
